Alpha 2.0
Login Register
» Authors » Hana Alharbi

Hana Alharbi

Explore the profile of Hana Alharbi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 11
Citations 95
Followers 0
Related Specialties
Biochemistry
Pharmacology
Molecular Biology
Top 10 Co-Authors
Miao He
Andrew C Edmondson
Rebecca D Ganetzky
Christina Lam
Jerry Vockley
Xinying Hong
Jessica R C Priestley
Stephen R Master
Yudong Wang
Gregory M Enns
Published In
Clin Chem
Hum Mol Genet
J Inherit Metab Dis
Case Rep Hematol
Int J Neonatal Screen
Affiliations
Soon will be listed here.
Recent Articles
1.
Causes of mortality in the congenital disorders of glycosylation
Alharbi H, Horikoshi S, Jenkins S, Scaglia F, Lam C, Morava E, et al.
Mol Genet Metab . 2025 Feb; 144(3):109052. PMID: 39923392
Congenital Disorders of Glycosylation (CDG) are a group of some 200 genetic disorders with PMM2-CDG being the most common disease. These disorders individually remain rare with poorly understood natural history...
2.
Potential cardioprotective effect of paroxetine against ventricular remodeling in an animal model of myocardial infarction: a comparative study
Alonazi A, Almodawah S, Aldigi R, Bin Dayel A, Alamin M, Almotairi A, et al.
BMC Pharmacol Toxicol . 2024 Dec; 25(1):99. PMID: 39696491
Background: Post-myocardial infarction (MI) remodeling involves various structural and functional changes, such as inflammation and fibrosis. Upregulation of G protein-coupled receptor kinase 2 (GRK2) is linked to the progression of...
3.
Fractionated plasma N-glycan profiling of novel cohort of ATP6AP1-CDG subjects identifies phenotypic association
Alharbi H, Daniel E, Thies J, Chang I, Goldner D, Ng B, et al.
J Inherit Metab Dis . 2023 Jan; 46(2):300-312. PMID: 36651831
ATP6AP1-CDG is an X-linked disorder typically characterized by hepatopathy, immunodeficiency, and an abnormal type II transferrin glycosylation pattern. Here, we present 11 new patients and clinical updates with biochemical characterization...
4.
A 6-Month-Old Infant with Severe Failure to Thrive during COVID-19 Pandemic
Hong X, Alharbi H, Albokhari D, Edmondson A, He M
Clin Chem . 2022 Jul; 68(7):987-989. PMID: 35780510
No abstract available.
5.
Fine-Tuning 3-Methylglutaconic Aciduria Cutoffs for a Patient with Infantile-Onset Barth Syndrome
Alharbi H, Hong X, Ritter A, Ahrens-Nicklas R, Master S, He M
Clin Chem . 2022 Feb; 68(2):365-367. PMID: 35104856
No abstract available.
6.
Normal Biomarkers in an Acute Presentation in a Known Case of Medium-Chain Acyl-Coenzyme A Dehydrogenase Deficiency
Alharbi H, Bennett M, He M, Master S, Ganetzky R
Clin Chem . 2021 Dec; 67(12):1735-1737. PMID: 34850845
No abstract available.
7.
Mitochondrial Hepatopathies
Alharbi H, Priestley J, Wilkins B, Ganetzky R
Clin Liver Dis (Hoboken) . 2021 Nov; 18(5):243-250. PMID: 34840726
No abstract available.
8.
The Importance of Succinylacetone: Tyrosinemia Type I Presenting with Hyperinsulinism and Multiorgan Failure Following Normal Newborn Screening
Priestley J, Alharbi H, Callahan K, Guzman H, Payan-Walters I, Smith L, et al.
Int J Neonatal Screen . 2020 Aug; 6(2). PMID: 32832707
Tyrosinemia type 1 (TT1) is an inborn error of tyrosine metabolism with features including liver dysfunction, cirrhosis, and hepatocellular carcinoma; renal dysfunction that may lead to failure to thrive and...
9.
Urinary Uracil: A Useful Marker for Ornithine Transcarbamylase Deficiency in Affected Males
Alsharhan H, Alharbi H, Priestley J, Ganetzky R, He M
Clin Chem . 2020 Jul; 66(7):988-989. PMID: 32628763
No abstract available.
10.
Mitochondrial fatty acid oxidation and the electron transport chain comprise a multifunctional mitochondrial protein complex
Wang Y, Palmfeldt J, Gregersen N, Makhov A, Conway J, Wang M, et al.
J Biol Chem . 2019 Jun; 294(33):12380-12391. PMID: 31235473
Three mitochondrial metabolic pathways are required for efficient energy production in eukaryotic cells: the electron transfer chain (ETC), fatty acid β-oxidation (FAO), and the tricarboxylic acid cycle. The ETC is...